{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037827","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.716773+00:00","generated_at":"2026-06-08T08:55:02.720690+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vanda Q3 net product sales $38.8M, down 41% YoY; generic Hetlioz hurts; two PDUFA dates in H1 2024","bullets":["Q3 2023 net product sales $38.8M vs $65.3M YoY; net income $0.1M ($0.00 EPS) vs $3.3M ($0.06) prior year.","Hetlioz sales fell 58% to $17.5M due to at-risk generic launch; Fanapt sales $21.3M, down 11%.","FDA accepted sNDAs: Fanapt for bipolar I (PDUFA Apr 2, 2024) and Hetlioz for insomnia (PDUFA Mar 4, 2024).","Tradipitant NDA for gastroparesis ongoing; Phase III motion sickness study over 20% enrolled.","Vanda to file Supreme Court petition by Jan 12, 2024 in Hetlioz ANDA litigation vs Teva/Apotex."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037827","json":"https://secwatch.observer/filing/0001628280-23-037827.json","markdown":"https://secwatch.observer/filing/0001628280-23-037827.md","text":"https://secwatch.observer/filing/0001628280-23-037827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023037827/0001628280-23-037827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023037827/vnda-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:55:02.720690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1d487d1190968ad2db68cf974d0546fa5299b48","claim":"Vanda Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue $38.8 million, net income $0.1 million.","evidence_excerpt":"Total net product sales from HETLIOZ ® and Fanapt ® were $38.8 million in the third quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023037827/0001628280-23-037827-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$38.8 million"},{"label":"Net income","value":"$0.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}